North America Central Precocious Puberty (CPP) Treatment Market - Industry Trends and Forecast to 2027

Report ID: | Publihed: 08-Jan-2020 | No of Pages: 90


USD 3995
USD 5795

Publish Date:


Total pages:


North America central precocious puberty (CPP) market is projected to register a CAGR of 7.2% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
North America Central Precocious Puberty (CPP) Treatment Market, By Type (Medication, Surgery), Month (1-Month, 2-Month, 6-Month, Others), Route of Administration (Parenteral, Implants, Oral, Others), Gender (Girls, Boys), End User (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others), Country (U.S., Canada, Mexico) Industry Trends & Forecast to 2027

Some of the major factors contributing to the growth of North America central precocious puberty (CPP) treatment market are:

• Growing prevalence of hormonal disorders
• Favorable government support for product approval

Market Players:

The key market players for North America central precocious puberty (CPP) market are listed below:

• Ipsen Pharma
• AbbVie Inc.
• Mylan N.V
• Pfizer Inc.
• Zydus Pharmaceuticals, Inc. (a subsidiary of Zydus Cadila)
• Teva Pharmaceutical USA, Inc. (a subsidiary of Teva Pharmaceutical Industries Ltd.)
• Takeda Pharmaceutical Company Limited
• Sanofi
• Arbor Pharmaceuticals
• Tolmar Pharmaceuticals, Inc.
• AstraZeneca
• Sun Pharmaceutical Industries Ltd
• Endo International plc

Report Subsumes the following

Competitors Analysis Go To Market Strategies
Regional Coverage with precise Market Numbers Global Impact post Covid-19
Market Penetration Strategies Granular breakdown By Type and By Application.